Dr. Croghan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1994 - 1997- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1991 - 1994
SUNY at Buffalo Graduate Medical-Dental Education Consortium (Millard Fillmore)Internship, Internal Medicine, 1990 - 1991- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1990
Roswell Park Cancer InstitutePost-Doctoral Fellowship, 1982 - 1986
Certifications & Licensure
MN State Medical License 1991 - 2025
Awards, Honors, & Recognition
- Mayo Teachers' Hall of Fame Inductee Mayo Cinic, Rochester, Minnesota, 2008
- Summa Cum Laude with Thesis Honors SUNY at Buffalo Medical School, 1990
- PhD General Experimental Pathology Roswell Park Cancer Institute, 1983
Clinical Trials
- Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Start of enrollment: 2005 Oct 01
- Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2006 Oct 01
Publications & Presentations
PubMed
- 13 citationsUp-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.Elizabeth Ann T. Lieser, Gary A. Croghan, Wendy K. Nevala, Michael J. Bradshaw, Svetomir N. Markovic
Lung Cancer. 2013-10-01 - 16 citationsPhase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji Kumar, James R. Jett, Randolph S. Marks, Ronald L. Richardson, Fernando Quevedo
Investigational New Drugs. 2013-07-26 - 2 citationsIs age ≥ 70 years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trialsAminah Jatoi, Jacob B. Allred, Vera J. Suman, Edward T. Creagan, Gary A. Croghan
Journal of Geriatric Oncology. 2012-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
